GLP-1 receptor agonists, reminder of potential side effects

The Medicines and Healthcare products Regulatory Agency (MHRA) has published a drug safety update for glucagon-like peptide-1 receptor agonists (GLP-1RAs). Healthcare professionals are reminded to inform patients about the common and serious side effects associated with GLP-1RAs, and to be aware there have been reports of potential misuse of GLP-1RAs for unauthorised indications such as aesthetic weight loss.

It is important that patients are aware of the potential adverse drug reactions associated with these medicines. These include common gastrointestinal reactions, that, if not managed effectively, can lead to serious complications.

Pharmacists should be aware that hypoglycaemia can occur in non-diabetic patients using some GLP-1RAs for weight management; ensure patients are aware of the symptoms and signs of hypoglycaemia and know to urgently seek medical advice should they occur.

There has been anecdotal evidence and adverse drug reaction reports suggesting misuse of GLP-1RA products for weight management by individuals outside of the licensed indication. The benefits and risks of using these medicines for weight loss by individuals who do not have obesity or who are not overweight with weight-related comorbidities have not been studied.

Further information and advice can be found on the MHRA website.